-
1.发明授权公开(公告)号：US10058540B2
公开(公告)日：2018-08-28
申请号：US15524565
申请日：2015-11-09
Applicant: H. Lundbeck A/S
Inventor： Karsten Juhl , Lena Tagmose , Mauro Marigo
IPC: A61K31/455 , A61K31/4178 , A61K31/422 , A61K31/42 , A61K31/427 , A61K31/4418 , A61K31/4427 , A61K31/444 , A61K31/497 , A61K31/506 , C07D211/68 , C07D401/12 , C07D413/12 , C07D417/12 , A61K31/4439
CPC classification number: A61K31/4439 , A61K31/444 , A61K31/497 , A61K31/506 , C07D401/12 , C07D413/12
Abstract: The present invention is directed to compounds of Formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of Aβ deposits is beneficial such as Alzheimer's disease.
-
公开(公告)号：US10004738B2
公开(公告)日：2018-06-26
申请号：US15231182
申请日：2016-08-08
Applicant: H. Lundbeck A/S
Inventor： Karsten Juhl , Mauro Marigo , Lena Tagmose , Thomas Jensen
IPC: A61K31/506 , A61K45/06 , A61K31/13 , A61K31/27 , A61K31/343 , A61K31/44 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/445 , A61K31/497 , A61K31/5415 , A61K31/55
CPC classification number: A61K31/506 , A61K31/13 , A61K31/27 , A61K31/343 , A61K31/44 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/445 , A61K31/497 , A61K31/5415 , A61K31/55 , A61K45/06 , A61K2300/00
Abstract: The present invention is directed to the combined use of BACE1 inhibitor of Formula I and a compound useful in active or passive Tau immunotherapy, a compound useful in active or passive Aβ peptide immunotherapy, an NMDA receptor antagonists, an acetylcholine esterase inhibitor, an antiepileptic, an anti-inflammatory drug, a Tau aggregation inhibitor or an SSRI for the treatment of neurodegenerative or cognitive disorders.
-
公开(公告)号：US20180016330A1
公开(公告)日：2018-01-18
申请号：US15645442
申请日：2017-07-10
Applicant: H. Lundbeck A/S
Inventor： Jan Torleif Pedersen , Kristian Kjærgaard , Lars Østergaard Pedersen , Abdur-Rasheed Asuni , Nina Helen Rosenqvist , Justus Claus Alfred Daechsel , Karsten Juhl , Lena Tagmose , Mauro Marigo , Thomas Jensen , Søren Christensen , Laurent David , Christiane Volbracht , Lone Helboe
Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
-
4.发明申请公开(公告)号：US20190000823A1
公开(公告)日：2019-01-03
申请号：US16059715
申请日：2018-08-09
Applicant: H. Lundbeck A/S
Inventor： Karsten Juhl , Lena Tagmose , Mauro Marigo
IPC: A61K31/4439 , C07D417/12 , C07D401/12 , C07D413/12
Abstract: The present invention is directed to compounds of formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of Aβ deposits is beneficial such as Alzheimer's disease.
-
![2-AMINO-7A-PHENYL-3,4,4A,5,7,7A-HEXAHYDROFURO[3,4-B]PYRIDINES AS BACE1 INHIBITORS](/abs-image/US/2018/08/16/US20180230160A1/abs.jpg.150x150.jpg)
公开(公告)号：US20180230160A1
公开(公告)日：2018-08-16
申请号：US15751777
申请日：2016-08-10
Applicant: H. Lundbeck A/S
Inventor： Karsten Juhl , Lena Tagmose , Mauro Marigo , Ask Puschl
IPC: C07D491/04 , A61P25/28
CPC classification number: C07D491/04 , A61P25/28
Abstract: Compounds of the Formula (I) are provided which compounds inhibitors of BACE1.
-
Patent Agency Ranking
6.发明申请Combination Treatment Comprising Administration of 2-Amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines 有权组合治疗包括给予2-氨基-3,5,5-三氟-3,4,5,6-四氢吡啶公开(公告)号：US20170042895A1
公开(公告)日：2017-02-16
申请号：US15231182
申请日：2016-08-08
Applicant: H. Lundbeck A/S
Inventor： Karsten Juhl , Mauro Marigo , Lena Tagmose , Thomas Jensen
IPC: A61K31/506 , A61K31/44 , A61K31/497 , A61K31/4439 , A61K31/444 , A61K45/06
CPC classification number: A61K31/506 , A61K31/13 , A61K31/27 , A61K31/343 , A61K31/44 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/445 , A61K31/497 , A61K31/5415 , A61K31/55 , A61K45/06 , A61K2300/00
Abstract: The present invention is directed to the combined use of BACE1 inhibitor of Formula I and a compound useful in active or passive Tau immunotherapy, a compound useful in active or passive Aβ peptide immunotherapy, an NMDA receptor antagonists, an acetylcholine esterase inhibitor, an antiepileptic, an anti-inflammatory drug, a Tau aggregation inhibitor or an SSRI for the treatment of neurodegenerative or cognitive disorders.
Abstract translation: 可用于活性或被动Tau免疫治疗的化合物，可用于活性或被动Aβ肽免疫治疗的化合物，NMDA受体拮抗剂，乙酰胆碱酯酶抑制剂，抗癫痫药，抗炎药，Tau聚集抑制剂或SSRI用于 治疗神经变性或认知障碍。
-
7.发明授权公开(公告)号：US10045974B2
公开(公告)日：2018-08-14
申请号：US15524546
申请日：2015-11-09
Applicant: H. Lundbeck A/S
Inventor： Karsten Juhl , Lena Tagmose , Mauro Marigo
IPC: C07D401/12 , A61K31/4439 , C07D417/12 , C07D413/12
Abstract: The present invention is directed to compounds of formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of Aβ deposits is beneficial such as Alzheimer's disease.
-
公开(公告)号：US20180186769A1
公开(公告)日：2018-07-05
申请号：US15848013
申请日：2017-12-20
Applicant: H. Lundbeck A/S
Inventor： Karsten Juhl , Lena Tagmose , Mauro Marigo
IPC: C07D401/12 , A61P25/28
CPC classification number: C07D401/12 , A61P25/28
Abstract: The invention provides amidine compounds of Formula I for the treatment of neurodegenerative or cognitive diseases, including Alzheimer's Disease.
-
9.发明申请公开(公告)号：US20170340618A1
公开(公告)日：2017-11-30
申请号：US15524565
申请日：2015-11-09
Applicant: H. Lundbeck A/S
Inventor： Karsten Juhl , Lena Tagmose , Mauro Marigo
IPC: A61K31/4439 , A61K31/506 , A61K31/444 , A61K31/497 , C07D413/12 , C07D401/12
CPC classification number: A61K31/4439 , A61K31/444 , A61K31/497 , A61K31/506 , C07D401/12 , C07D413/12
Abstract: The present invention is directed to compounds of Formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of Aβ deposits is beneficial such as Alzheimer's disease.
-
10.发明申请公开(公告)号：US20170319564A1
公开(公告)日：2017-11-09
申请号：US15524546
申请日：2015-11-09
Applicant: H. Lundbeck A/S
Inventor： Karsten Juhl , Lena Tagmose , Mauro Marigo
IPC: A61K31/4439 , C07D401/12 , C07D413/12 , C07D417/12
CPC classification number: A61K31/4439 , C07D401/12 , C07D413/12 , C07D417/12
Abstract: The present invention is directed to compounds of formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of Aβ deposits is beneficial such as Alzheimer's disease.
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.021 seconds)
